Christopher M Starr, Director at Monopar Therapeutics, sold MNPR on Oct 1, 2026
Data as of Oct 16
- Traded
- Oct 1, 2026
- Disclosed
- Oct 5, 2026
- Filed
- 4 days after the trade
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
MNPR since disclosure
−11.5%
after the sale
Similar stocks (XLV) since disclosure
+5.6%
XLV — its sector index fund
Change in closing price from Oct 5, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.
Our take
None of our tested rules fired on this trade.
Other trades in the same filing
- ▼ SELLChristopher M Starr DirectorMNPR Monopar Therapeutics$234Kdisclosed Oct 5 · filed 4 days after the trade
- ▼ SELLChristopher M Starr DirectorMNPR Monopar Therapeutics$362Kdisclosed Oct 5 · filed 4 days after the trade